Search Tag: hepatocellular carcinoma
2025 09 Nov
Hepatocellular carcinoma (HCC) continues to drive significant morbidity and mortality. Microvascular invasion (MVI) is a key marker of aggressive biology, yet confirmation usually arrives only after surgery. An MRI-based approach now captures how uneven the tumour and its immediate surroundings appear on routine sequences, turning those patterns...Read more
2025 31 Oct
Primary liver cancer is a major cause of cancer-related death and hepatocellular carcinoma (HCC) accounts for most cases. Surveillance aims to find disease earlier in people at risk, yet ultrasound, the main tool for routine monitoring, can miss small or subtle lesions. More intensive imaging can detect disease earlier but is demanding for services...Read more
2025 31 Oct
Primary liver cancer is a major cause of cancer-related death and hepatocellular carcinoma (HCC) accounts for most cases. Surveillance aims to find disease earlier in people at risk, yet ultrasound, the main tool for routine monitoring, can miss small or subtle lesions. More intensive imaging can detect disease earlier but is demanding for services...Read more
2025 31 Oct
Primary liver cancer is a major cause of cancer-related death and hepatocellular carcinoma (HCC) accounts for most cases. Surveillance aims to find disease earlier in people at risk, yet ultrasound, the main tool for routine monitoring, can miss small or subtle lesions. More intensive imaging can detect disease earlier but is demanding for services...Read more
2025 29 Sep
Knowing how aggressive a liver tumour is before treatment can shape decisions on surgery and follow-up. Pathology remains the benchmark for confirming tumour behaviour, yet it becomes available only after resection. Contrast-enhanced ultrasound (CEUS) provides a real-time view of blood flow in and around hepatocellular carcinoma, but visual interpretation...Read more
2025 29 Sep
Knowing how aggressive a liver tumour is before treatment can shape decisions on surgery and follow-up. Pathology remains the benchmark for confirming tumour behaviour, yet it becomes available only after resection. Contrast-enhanced ultrasound (CEUS) provides a real-time view of blood flow in and around hepatocellular carcinoma, but visual interpretation...Read more
2025 09 Sep
Accurate preoperative distinction between hepatocellular carcinoma, intrahepatic cholangiocarcinoma and hepatic inflammatory pseudotumour remains difficult on routine imaging and serum markers, yet the consequences are significant. HCC and ICC often require surgery or systemic therapy, whereas HIPT is benign and may be managed conservatively,...Read more
2025 02 Sep
Microvascular invasion is a key histopathological feature linked to recurrence and poor survival in hepatocellular carcinoma, yet it is confirmed only after surgery, limiting its value for preoperative decision-making. A retrospective multicentre analysis of 655 surgically confirmed cases explored whether three-dimensional fractal dimension derived...Read more
2025 02 Sep
Microvascular invasion is a key histopathological feature linked to recurrence and poor survival in hepatocellular carcinoma, yet it is confirmed only after surgery, limiting its value for preoperative decision-making. A retrospective multicentre analysis of 655 surgically confirmed cases explored whether three-dimensional fractal dimension derived...Read more
2025 12 Aug
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with cases projected to rise to 1.4 million annually by 2040. Many patients are diagnosed at advanced stages, requiring systemic therapies such as sorafenib, lenvatinib, atezolizumab–bevacizumab and tremelimumab–durvalumab. While these treatments can extend...Read more
2025 25 Mar
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide, ranking as the third leading cause of cancer-related deaths. Despite advancements in diagnostic and therapeutic approaches, the prognosis for patients with advanced HCC remains poor, with five-year survival rates as low as 18%. A major contributing factor...Read more
2025 25 Mar
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide, ranking as the third leading cause of cancer-related deaths. Despite advancements in diagnostic and therapeutic approaches, the prognosis for patients with advanced HCC remains poor, with five-year survival rates as low as 18%. A major contributing factor...Read more
2025 24 Feb
Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the leading causes of cancer-related mortality worldwide. Despite advancements in therapeutic options, the variability in patient responses highlights a significant challenge in personalising treatment. Understanding this heterogeneity is crucial for improving outcomes....Read more